Literature DB >> 16189008

Structure of the Fab fragment of F105, a broadly reactive anti-human immunodeficiency virus (HIV) antibody that recognizes the CD4 binding site of HIV type 1 gp120.

Royce A Wilkinson1, Chayne Piscitelli, Martin Teintze, Lisa A Cavacini, Marshall R Posner, C Martin Lawrence.   

Abstract

We have determined the crystal structure of the Fab fragment from F105, a broadly reactive human antibody with limited potency that recognizes the CD4 binding site of gp120. The structure reveals an extended CDR H3 loop with a phenylalanine residue at the apex and shows a striking pattern of serine and tyrosine residues. Modeling the interaction between gp120 and F105 suggests that the phenylalanine may recognize the binding pocket of gp120 used by Phe(43) of CD4 and that numerous tyrosine and serine residues form hydrogen bonds with the main chain atoms of gp120. A comparison of the F105 structure to that of immunoglobulin G1 b12, a much more potent and broadly neutralizing antibody with an overlapping epitope, suggests similarities that contribute to the broad recognition of human immunodeficiency virus by both antibodies. While the putative epitope for F105 shows significant overlap with that predicted for b12, it appears to differ from the b12 epitope in extending across the interface between the inner and outer domains of gp120. In contrast, the CDR loops of b12 appear to interact predominantly with the outer domain of gp120. The difference between the predicted epitopes for b12 and F105 suggests that the unique potency of b12 may arise from its ability to avoid the interface between the inner and outer domains of gp120.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16189008      PMCID: PMC1235812          DOI: 10.1128/JVI.79.20.13060-13069.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  70 in total

1.  Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope.

Authors:  Ramalakshmi Darbha; Sanjay Phogat; Aran F Labrijn; Yuuei Shu; Yijun Gu; Michelle Andrykovitch; Mei-Yun Zhang; Ralph Pantophlet; Loic Martin; Claudio Vita; Dennis R Burton; Dimiter S Dimitrov; Xinhua Ji
Journal:  Biochemistry       Date:  2004-02-17       Impact factor: 3.162

2.  QSYP peptide sequence is selected from phage display libraries by bovine IgG contaminants in monoclonal antibody preparations.

Authors:  J M Jacobs; B W Bailey; J B Burritt; S G Morrison; R P Morrison; E A Dratz; A J Jesaitis; M Teintze
Journal:  Biotechniques       Date:  2003-01       Impact factor: 1.993

3.  Probability analysis of variational crystallization and its application to gp120, the exterior envelope glycoprotein of type 1 human immunodeficiency virus (HIV-1).

Authors:  P D Kwong; R Wyatt; E Desjardins; J Robinson; J S Culp; B D Hellmig; R W Sweet; J Sodroski; W A Hendrickson
Journal:  J Biol Chem       Date:  1999-02-12       Impact factor: 5.157

4.  Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein.

Authors:  J Cao; N Sullivan; E Desjardin; C Parolin; J Robinson; R Wyatt; J Sodroski
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

5.  Structural characterization of broadly neutralizing human monoclonal antibodies against the CD4 binding site of HIV-1 gp120.

Authors:  J Bagley; P J Dillon; C Rosen; J Robinson; J Sodroski; W A Marasco
Journal:  Mol Immunol       Date:  1994-10       Impact factor: 4.407

Review 6.  Passive immunization with human neutralizing monoclonal antibodies: correlates of protective immunity against HIV.

Authors:  Weidong Xu; Regina Hofmann-Lehmann; Harold M McClure; Ruth M Ruprecht
Journal:  Vaccine       Date:  2002-05-06       Impact factor: 3.641

7.  Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120.

Authors:  Michael B Zwick; Paul W H I Parren; Erica O Saphire; Sarah Church; Meng Wang; Jamie K Scott; Philip E Dawson; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

8.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

9.  Expressed murine and human CDR-H3 intervals of equal length exhibit distinct repertoires that differ in their amino acid composition and predicted range of structures.

Authors:  Michael Zemlin; Martin Klinger; Jason Link; Cosima Zemlin; Karl Bauer; Jeffrey A Engler; Harry W Schroeder; Perry M Kirkham
Journal:  J Mol Biol       Date:  2003-12-05       Impact factor: 5.469

Review 10.  Interactions of protein antigens with antibodies.

Authors:  D R Davies; G H Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

View more
  19 in total

1.  In vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120.

Authors:  Maria Luisa Visciano; Michael Tuen; Miroslaw K Gorny; Catarina E Hioe
Journal:  Virology       Date:  2007-12-04       Impact factor: 3.616

2.  The Ixodes scapularis salivary protein, salp15, prevents the association of HIV-1 gp120 and CD4.

Authors:  Ignacio J Juncadella; Renu Garg; Tonya C Bates; Elias R Olivera; Juan Anguita
Journal:  Biochem Biophys Res Commun       Date:  2007-12-26       Impact factor: 3.575

3.  Contribution of asparagine residues to the stabilization of a proteinaceous antigen-antibody complex, HyHEL-10-hen egg white lysozyme.

Authors:  Akiko Yokota; Kouhei Tsumoto; Mitsunori Shiroishi; Takeshi Nakanishi; Hidemasa Kondo; Izumi Kumagai
Journal:  J Biol Chem       Date:  2009-12-28       Impact factor: 5.157

4.  Characterization of a discontinuous epitope of the HIV envelope protein gp120 recognized by a human monoclonal antibody using chemical modification and mass spectrometric analysis.

Authors:  Christine Hager-Braun; Elisabeth O Hochleitner; Miroslaw K Gorny; Susan Zolla-Pazner; Rachelle J Bienstock; Kenneth B Tomer
Journal:  J Am Soc Mass Spectrom       Date:  2010-03-31       Impact factor: 3.109

5.  Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.

Authors:  Nina R Derby; Zane Kraft; Elaine Kan; Emma T Crooks; Susan W Barnett; Indresh K Srivastava; James M Binley; Leonidas Stamatatos
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

6.  Pradimicin A, a carbohydrate-binding nonpeptidic lead compound for treatment of infections with viruses with highly glycosylated envelopes, such as human immunodeficiency virus.

Authors:  Jan Balzarini; Kristel Van Laethem; Dirk Daelemans; Sigrid Hatse; Antonella Bugatti; Marco Rusnati; Yasuhiro Igarashi; Toshikazu Oki; Dominique Schols
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

7.  Conformational and structural features of HIV-1 gp120 underlying the dual receptor antagonism by cross-reactive neutralizing antibody m18.

Authors:  Syna Kuriakose Gift; Isaac J Zentner; Arne Schön; Karyn McFadden; M Umashankara; Srivats Rajagopal; Mark Contarino; Caitlin Duffy; Joel R Courter; Mei-Yun Zhang; Jonathan M Gershoni; Simon Cocklin; Dimiter S Dimitrov; Amos B Smith; Ernesto Freire; Irwin M Chaiken
Journal:  Biochemistry       Date:  2011-03-18       Impact factor: 3.162

8.  Comprehensive optimization of a single-chain variable domain antibody fragment as a targeting ligand for a cytotoxic nanoparticle.

Authors:  Kathy Zhang; Melissa L Geddie; Neeraj Kohli; Tad Kornaga; Dmitri B Kirpotin; Yang Jiao; Rachel Rennard; Daryl C Drummond; Ulrik B Nielsen; Lihui Xu; Alexey A Lugovskoy
Journal:  MAbs       Date:  2015       Impact factor: 5.857

9.  Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120.

Authors:  Lei Chen; Young Do Kwon; Tongqing Zhou; Xueling Wu; Sijy O'Dell; Lisa Cavacini; Ann J Hessell; Marie Pancera; Min Tang; Ling Xu; Zhi-Yong Yang; Mei-Yun Zhang; James Arthos; Dennis R Burton; Dimiter S Dimitrov; Gary J Nabel; Marshall R Posner; Joseph Sodroski; Richard Wyatt; John R Mascola; Peter D Kwong
Journal:  Science       Date:  2009-11-20       Impact factor: 47.728

10.  Crystal structure of the neutralizing Llama V(HH) D7 and its mode of HIV-1 gp120 interaction.

Authors:  Andreas Hinz; David Lutje Hulsik; Anna Forsman; Willie Wee-Lee Koh; Hassan Belrhali; Andrea Gorlani; Hans de Haard; Robin A Weiss; Theo Verrips; Winfried Weissenhorn
Journal:  PLoS One       Date:  2010-05-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.